Glycosylated protein expression in prokaryotes
The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyl-transferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.
1. A method for producing an N-linked glycosylated protein comprising:
providing a recombinant prokaryotic host cell expressing one or more eukaryotic UDP-GlcNAc transferase enzymes, one or more eukaryotic mannosyltransferase enzymes, and a prokaryotic oligosaccharyltransferase enzyme capable of transferring a eukaryotic glycan to an N-glycosylation acceptor site of a protein, said acceptor site comprising N-X-S/T, and
culturing said host cell under conditions effective to:
(i) produce a eukaryotic glycan linked to a bactoprenol lipid carrier molecule, and
(ii) transfer the eukaryotic glycan to the N-glycosylation acceptor site of the protein to produce the N-linked glycosylated protein.
2. The method of claim 1 , wherein the one or more UDP-GlcNAc transferase enzymes are selected from an Alg13 enzyme, an Alg14 enzyme, or a combination thereof.
3. The method of claim 1 , wherein the one or more mannosyltransferase enzymes are selected from an Alg1 enzyme, an Alg2 enzyme, or a combination thereof.
4. The method of claim 1 , wherein the prokaryotic host cell further comprises a flippase activity.
5. The method of claim 1 , wherein the N-linked glycosylated protein is a glycosylated antibody comprising:
an Fv portion which binds to a native antigen and
an Fc portion which is glycosylated at a conserved asparagine residue.
6. The method of claim 1 , wherein the N-linked glycosylated protein is selected from the group consisting of erythropoietins, cytokines, interferons, G-CSF, coagulation factors, factor VIII, factor IX, human protein C, soluble IgE receptor alpha-chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion protein, angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, alpha-1 antitrypsin, DNase II, alpha-feto proteins, TNF binding protein I (rhTBP-1), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI-Ig), follicle stimulating hormone (FSH), GM-CSF, glucagon like protein I (GLP-1), IL-1 receptor agonist, soluble TNF receptor Fc fusion (sTNFr), ATIII, rhThrombin, glucocerebrosidase, Cytotoxic T Lymphocyte associated Antigen 4-Ig (CTLA4-Ig), and serum albumin.
7. The method of claim 1 , wherein the prokaryotic host cell further comprises an attenuation, disruption or deletion of competing sugar biosynthesis reactions.
8. The method of claim 1 , wherein the eukaryotic glycan comprises GlcNAc 2 .
9. The method of claim 8 , wherein the eukaryotic glycan further comprises at least one mannose residue.
10. The method of claim 8 , wherein the eukaryotic glycan comprises Man 3 GlcNAc 2 .
11. The method of claim 1 , wherein the eukaryotic glycan is a human glycan.